Immutep Limited (ASX:IMM) Launches Major Phase III Trial Targeting Lung Cancer

3 min read | March 25, 2025 03:06 PM AEDT | By Team Kalkine Media

Google News:

Immutep Limited (ASX:IMM) Launches Major Phase III Trial Targeting Lung Cancer — Image source: Shutterstock

Recent News

Are ASX Metal & Mining Stocks Entering a New Market Phase?

The Hidden Forces That Could Reshape ASX Metal & Mining Stocks

ASX Metal & Mining Stocks: The Market Watchlist Investors Cannot Ignor...

Hidden Forces That Could Reshape ASX Lithium Stocks in 2026

Make Kalkine Media
My Trusted Source

Highlights

Immutep Limited (IMM) begins pivotal Phase III trial for lung cancer treatment.

The global study aims to enroll over 750 patients in 25+ countries.

Potential for setting a new standard of care in treating advanced lung cancer.

In a significant advancement for cancer research, Immutep Limited (ASX:IMM) has commenced the TACTI-004 Phase III trial, aimed at transforming the treatment landscape for non-small cell lung cancer. The pivotal trial recently began with the dosing of the first patient at Calvary Mater Newcastle Hospital in Australia, marking a milestone in the company’s pursuit of innovative cancer therapies. This development is of particular interest to investors tracking ASX-listed healthcare stocks, as advancements in such trials can significantly impact these companies' market performance and investor sentiment.

The TACTI-004 trial is designed to evaluate the effectiveness and safety of a novel therapeutic combination in patients suffering from metastatic or advanced non-small cell lung cancer. This global trial is expected to involve approximately 756 patients and will span more than 150 clinical sites across over 25 countries worldwide.

The treatment being tested involves 'efti' in combination with KEYTRUDA, a well-known therapy in oncological treatments. This combination is anticipated to offer a clinically meaningful improvement in survival rates, aiming to establish a new standard of care for patients battling this severe form of lung cancer.

Marc Voigt, the CEO of Immutep, expressed optimism about the trial's potential impact, stating that the initiation of this Phase III trial represents one of the most critical milestones in the company's history. He emphasized the significance of the study in potentially altering clinical practices, offering new hope for patients who are in desperate need of more effective treatment options.

As the study progresses, the oncology community and investors are keenly watching, given the high prevalence and impact of lung cancer globally. Non-small cell lung cancer, the focus of this trial, accounts for a significant portion of lung cancer cases and is noted for its aggressive nature and limited treatment success rates in advanced stages.

Immutep's strategic approach to addressing this pressing medical need demonstrates their commitment to advancing healthcare and improving patient outcomes. The successful execution and positive results from this trial could not only benefit patients but also significantly enhance the company's valuation and position in the biotechnology market.

As this major trial moves forward, all eyes will be on Immutep Limited (ASX:IMM), eagerly anticipating the potential breakthroughs that might redefine cancer treatment paradigms and provide patients with a new lease on life.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.